Skip to content
Canada's trusted research peptide sourceFree shipping from $250 CADPurity-tested compoundsPay by Interac e-TransferCanadian owned & operatedFast, discreet shippingCOA-backed qualityCanada-onlyCanada's trusted research peptide sourceFree shipping from $250 CADPurity-tested compoundsPay by Interac e-TransferCanadian owned & operatedFast, discreet shippingCOA-backed qualityCanada-onlyCanada's trusted research peptide sourceFree shipping from $250 CADPurity-tested compoundsPay by Interac e-TransferCanadian owned & operatedFast, discreet shippingCOA-backed qualityCanada-onlyCanada's trusted research peptide sourceFree shipping from $250 CADPurity-tested compoundsPay by Interac e-TransferCanadian owned & operatedFast, discreet shippingCOA-backed qualityCanada-onlyCanada's trusted research peptide sourceFree shipping from $250 CADPurity-tested compoundsPay by Interac e-TransferCanadian owned & operatedFast, discreet shippingCOA-backed qualityCanada-onlyCanada's trusted research peptide sourceFree shipping from $250 CADPurity-tested compoundsPay by Interac e-TransferCanadian owned & operatedFast, discreet shippingCOA-backed qualityCanada-onlyCanada's trusted research peptide sourceFree shipping from $250 CADPurity-tested compoundsPay by Interac e-TransferCanadian owned & operatedFast, discreet shippingCOA-backed qualityCanada-onlyCanada's trusted research peptide sourceFree shipping from $250 CADPurity-tested compoundsPay by Interac e-TransferCanadian owned & operatedFast, discreet shippingCOA-backed qualityCanada-only
Journal

Research news

The AMA pushes back on peptide compounding.What changed this week.

The AMA voted to urge HHS to rescind its peptide compounding policy, and a US pharmacy announced plans under it. Here is what each step does and does not change.

By Proof Line Peptides · Published · 4 min read

BPC-157 10 mg labelled research vial

On November 9, 2026, the American Medical Association (AMA) adopted new policy on unapproved synthetic peptides. The vote took place at the Interim Meeting of the AMA House of Delegates in Orlando. It came less than two weeks after HHS announced an interim enforcement discretion policy covering six compounded peptides.

We covered that HHS notice in HHS names six peptides for compounding. This post looks at what has happened since. That includes the AMA's response, a pharmacy announcement under the policy, and what comes next.

What the AMA adopted

According to the AMA's press release, the new policy has two main parts.

  • The AMA will urge HHS, the FDA and other federal regulators to immediately rescind administrative policies or directives that ease restrictions on compounding and distributing synthetic peptides without FDA approval.
  • The AMA will work with federal agencies, state medical boards and state boards of pharmacy on strict oversight and enforcement against compounding pharmacies, direct-to-consumer telehealth platforms and online dispensaries distributing unapproved synthetic peptide formulations.

The release does not name a specific HHS document. Becker's Hospital Review pointed to the timing, which follows the HHS policy covering BPC-157, TB-500 and four other peptides.

AMA Board Member Ilse R. Levin, DO, said that compounding these substances without sufficient safety and efficacy evidence leaves patients at "increased risk of serious harm."

This was not the AMA's first comment. Its November 6 advocacy update reported that AMA President Willie Underwood III, MD, warned the then-proposed policy put patients at greater risk of preventable harm. The same update referenced an AMA letter to FDA raising concerns about inconsistent naming of these peptides and incomplete drug development work.

What an AMA policy can and cannot do

  • AMA policy is an advocacy position, not a regulation.
  • It does not withdraw or amend the HHS notice.
  • HHS has said it may revisit the interim policy if a safety signal or product quality issue arises.

A pharmacy announcement

On November 12, Olympia Pharmaceuticals, a Florida-based 503A pharmacy, announced it would begin compounding BPC-157 under the HHS policy. It said it plans to evaluate KPV, TB-500, MOTS-c, Semax and epitalon after that.

The announcement summarizes several conditions of the HHS policy:

  • One active ingredient per product.
  • A valid patient-specific prescription.
  • Labeling as a compounded product that is not for resale.
  • Limits on the authorized routes and product forms for each peptide, plus FDA 510(k)-cleared delivery devices.
  • Sourcing from FDA-registered manufacturers, ingredient testing, and adverse-event reporting to FDA MedWatch.

Where the evidence stands

Neither development adds new clinical data. FDA's Center for Drug Evaluation and Research had recommended against listing all six peptides, as the law firm Akin Gump notes in its summary of the notice. HHS justified each inclusion by pointing to characterization records, documented historical use and the safeguards built into the policy. None of those is an efficacy trial.

Our guides to BPC-157 and TB-500 reach a similar conclusion from the published papers. Most of the work on both is in cell cultures and animal models. For why that distinction matters, see Cell studies, animal models and human trials.

What comes next

  • The HHS notice was published in the Federal Register on October 30 with a two-week comment window, which points to a close around November 13.
  • The interim policy stays in place for each peptide until FDA addresses it in rulemaking on the 503A bulks list.
  • FDA's Pharmacy Compounding Advisory Committee plans to review another group of peptides at a meeting in February 2027.

For Canadian researchers

These are US developments about pharmacy compounding. They do not change the status of any of these substances in Canada. They also do not turn any of them into an authorized medicine. Our note on research materials and authorized medicines in Canada explains how to check Canadian product information.

Sources

For laboratory research use only. Not for human or veterinary use.

Shop the vials

Proof Line offers by email.

For laboratory research use only. Not for human or veterinary use.